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Abstract 
The advancement of biomedical named entity recognition (BNER) and biomedical 
relation extraction (BRE) researches promotes the development of text mining in 
biological domains. As a cornerstone of BRE, robust BNER system is required to 
identify the mentioned NEs in plain texts for further relation extraction stage. However, 
the current BNER corpora, which play important roles in these tasks, paid less attention 
to achieve the criteria for BRE task. In this study, we present Revised JNLPBA corpus, 
the revision of JNLPBA corpus, to broaden the applicability of a NER corpus from 
BNER to BRE task. We preserve the original entity types including protein, DNA, 
RNA, cell line and cell type while all the abstracts in JNLPBA corpus are manually 
curated by domain experts again basis on the new annotation guideline focusing on the 
specific NEs instead of general terms. Simultaneously, several imperfection issues in 
JNLPBA are pointed out and made up in the new corpus. To compare the adaptability 
of different NER systems in Revised JNLPBA and JNLPBA corpora, the F1-measure 
was measured in three open sources NER systems including BANNER, Gimli and 
NERSuite. In the same circumstance, all the systems perform average 10% better in 
Revised JNLPBA than in JNLPBA. Moreover, the cross-validation test is carried out 
which we train the NER systems on JNLPBA/Revised JNLPBA corpora and access the 
performance in both protein-protein interaction extraction (PPIE) and biomedical event 
extraction (BEE) corpora to confirm that the newly refined Revised JNLPBA is a 
competent NER corpus in biomedical relation application. The revised JNLPBA corpus 
is freely available at iasl-btm.iis.sinica.edu.tw/BNER/Content/Revised_JNLPBA.zip. 
1. Background and Motivation 
The application of natural language processing (NLP) is useful for biomedical scientists 
to retrieve valuable information from numerous biological publications. Among bio-
NLP tasks, biomedical named entity recognition (BNER) is the fundamental but critical 
one to conquer. Hence, there are many BNER corpora developed for this purpose. For 
instance, Arizona Disease Corpus (AZDC) [1] is one of the well-known bio-NER 
corpora. The AZDC corpus contains 793 PubMed abstracts for the disease entity 
recognition task which is less discussed. Moreover, GENIA corpus [2] is collected by 
retrieving abstracts associated with specific MEDLINE query terms such as “human”, 
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“blood cells” and “transcription factors”. Based on the GENIA ontology [3], the 
recruited knowledge is well-organized in this corpus. The release of the GENIA corpus 
promoted text-mining studies in the field of molecular biology and it serves as the seed 
for several tasks where truthful training and test sets can be constructed. 
However, the earlier NER corpora are gradually unsatisfactory to corresponding 
applications since the development of information extraction studies progresses rapidly 
ever than before. Take AZDC corpus as an example, the dataset is improved at the 
entity level and generated the specific identifiers from MeSH or OMIM databases for 
disease normalization [4]. In contrast to the more detailed corpus revision, combination 
of trivial concepts to hyper definitions is another direction to promote ideal corpus. The 
JNLPBA 2004 shared task [5] is derived from five superclasses in the GENIA corpus 
while the entities are named protein, DNA, RNA, cell line and cell type, respectively.  
Due to the complexity of the gene name nomenclature and composition [6], there are 
several ways to present gene entities in different gene mention corpora. In JNLPBA 
corpus, the gene mentions are divided into protein, DNA and RNA which included not 
only specific gene names but also corresponding general sequence information which 
are seldom referred to as interested entities in biological fields. Another gene mention 
dataset, GENETAG [7] rules out the general sequence mentions in annotations and 
considers protein, DNA and RNA as the same entity type since the inclusion allows to 
reduce the unnecessary disambiguation process. More recently, Gene and Protein 
Related Object (GPRO) task [8] builds up the GPRO corpus with proposing two types 
of entity mention definitions: GPRO entity mention type 1 and type 2. All the entities 
covered in GPRO entity mention type 1 are able to be normalized while entities in type 
2 are not. Nevertheless, the gene mentions in GPRO entity mention type 2 represent to 
the protein family terms or multiple gene mentions rather than the general bio-entities. 
Despite the standard of gene mentions annotations has been transformed from general 
gene mentions to more compatible annotation for relation extraction. However, the 
standard of original corpora still have their reputation, therefore, even recently 
published works still have to use these corpora to evaluate their approaches (despite the 
corpus annotations do not fit real application). Another common issue of earlier corpora 
is that they have either smaller scale or lower annotation consistency because they have 
to spend more efforts in collecting data and defining annotation standard. Therefore, if 
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a proposed algorithm uses the corpus for evaluation, and get poor results, it is hard to 
distinguish whether the lower performances come from their algorithm designs or not. 
In the paper, we developed a revised version of JNLPBA corpus. We believe that it 
would be an alternative option for those who use the JNLPBA corpus and get lower 
performance. Meanwhile, several odd situations found in original JNLPBA are pointed 
out with relevant cases to emphasize the necessity of corpus revision. It is especially 
helpful for those who cannot figure out whether the lower performances stand for the 
inappropriate algorithm designs or not. To measure the efficacy of using Revised 
JNLPBA, two experiments are conducted. Three widely mentioned NER systems 
(BANNER [9], Gimli [10] and NERsuite [11]) are introduced in both experiments to 
evaluate the corpora. In the first experiment, NER systems are trained on both corpora 
and tested in the corresponding test set. The performance can be a fair reference to 
judge the annotation consistency of each corpus. To further examine the adaptability 
of corpus after revision, we integrate five Protein-Protein Interaction Extraction (PPIE) 
and five Biomedical Event Extraction (BEE) corpora for the validation. All gene 
mentions in above relation extraction corpora are the prediction targets while the two 
JNLPBA corpora are utilized for training, respectively. 
By the comparisons between the Revised JNLPBA and before, users can select the 
preferable corpus for their projects according to the needs. In summary, the Revised 
JNLPBA corpus engages the purities of annotation for researchers who tend to focus 
on the specific gene mention identification instead of the DNA/protein sequences or 
the mentions of gene/protein fragments. Moreover, the elusive entity boundaries in the 
original corpus are also found and improved. Without the interference of the non-
specific terms and the boundary confusion, the defects hidden in the desired module is 
easier to be verified. Finally, the Revised JNLPBA broadens the corpus availability to 
explore the advanced relation extraction task which the included gene mentions show 
similar annotation criteria. 
 
2. JNLPBA Annotations 
In this section, we summarize the imperfections of current JNLPBA corpus and raise 
the explanations for why we consider that these types of annotations are inappropriate. 
The homogeneity of JNLPBA corpus is concerned since the entity types from the 
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superclass of GENIA ontology are not excluded the partial components in protein, 
DNA and RNA. Hence, the contents may present a bunch of noises due to different 
biological definitions are forced to be clustered together. For example, the partial 
protein regions such as “motif” and “domain” are not considered as entities in general 
biological NER tasks.  
Furthermore, given the increasing interest in applying BNER on Protein-Protein 
Interaction Extraction (PPIE) and Biomedical Event Extraction (BEE) tasks, the 
annotation standards are not compatible with these tasks. Below, we give some 
examples of problems found in the JNLPBA corpus. First, many general terms were 
recruited as entities, such as: 
“A construct termed PFP5a DNA  containing -795 bp DNA  exhibited the highest 
CAT protein  activity, and ...” 
The term “-795bp” is the position of the DNA sequence (counting from the 
transcription start site), which is not annotated in the PPIE and BEE corpora, but was 
referred to as a DNA in the JNLPBA corpus. 
Second, some entities include redundant preceding words that do not exist in the 
original name in the database. For example, “truncated RARalpha” is marked as a 
protein in JNLPBA, but the term “truncated” cannot provide any useful identity 
information to “RARalpha” and therefore should be excluded. 
In addition, due to the large size of the corpus, there are some missing annotations 
and incorrect assignment of BNE type in the JNLPBA corpus.  
Moreover, there are some inconsistencies that may cause misunderstandings if one 
attempts to map the entities back to the corresponding ID in standard databases or 
organize them into clusters. The inconsistencies can be generally classified into five 
types, including the recruitments of general terms, unnecessary preceding words, entity 
type confusion, neglected adjacent clues, and missing annotations. The following 
paragraphs describe examples regarding each type of the confusions that can be found 
in the GENIA corpus. 
 
2.1 Problem of general terms 
Specific entities containing unique names can be clearly recognized in the database or 
certain groups they belong to, while some entities possess only general properties. It is 
not appropriate for the latter type to be assigned the same label as the former. So, it is 
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better to remove the so-called general terms or assign other tags to them. The following 
example expresses the appearance of general terms: 
“Substitution mutations in this consensus sequence eliminate binding of the inducible 
factor.” 
MEDLINE: 97138389 
The bold terms are labeled as DNA and protein respectively in GENIA corpus but 
both of them lack the major features to become specific BNEs. 
 
2.2 Unnecessary preceding words 
The information beyond entities often provides intrinsic properties or external status to 
make the entities more intact. The intrinsic information is important to assist the 
assignments of correct identities, so it is suitable to be recruited as part of entities. For 
example, “human” and “murine” can serve as the evidence to separate the same “IL-2” 
into different gene IDs. However, extrinsic information sometimes could depict 
additional properties that are not helpful when distinguishing these entities. 
The following instance serves to illustrate this type of words: 
“Expression of dominant negative MAPKK-1 prevents NFAT induction.”  
MEDLINE: 96324400 
“MAPKK-1” is the core of bold terms, while “dominant negative” is regarded as a 
mutant type of protein. The latter biological term carries no useful message if one tries 
to find the real source of “MAPKK-1”. Table 1 gives the numbers of general terms and 
unnecessary preceding words in JNLPBA corpus.  
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Table 1. Statistics of general terms and unnecessary preceding words in JNLPBA 
corpus. 
 Training set Test set 
BNE 
type 
Num. 
of total 
NEs 
Num. of 
general 
terms 
Num. of 
unnecessary 
preceding 
words 
Num. 
of 
total 
NEs 
Num. of 
general 
terms 
Num. of 
unnecessary 
preceding 
words 
cell line 3,830 779 498 500 132 55 
cell type 6,718 1,006 1,757 1,921 174 327 
DNA 9,534 4,137 780 1,056 306 31 
protein 30,269 8,145 1,781 5,067 666 166 
RNA 951 268 84 118 16 7 
 
 
2.3 Entity type confusion 
Some entity types in the GENIA corpus are related to each other, and this association 
may sometimes cause misclassification of the entity type. By comparing the following 
two sentences, it is clear that labels are inconsistent. 
“… that the type II IL-1R does not mediate gene activation in Jurkat cells.”  
MEDLINE: 93252936 
“…galectin-3 was shown to activate interleukin-2 production in Jurkat T cells.”  
MEDLINE: 96208140 
The two similar bold entities are labeled as cell line and cell type, respectively, in 
this instance. However, the core term “Jurkat” is a powerful attribution to annotate both 
of them as cell line. 
 
2.4 Neglected adjacent clues 
In some cases, the entities are concatenated with a certain type of keywords, so it is 
easy to clarify the real types of entities. But several observations indicate that a few of 
the keywords are neglected in the GENIA corpus, such as the example below: 
“The 5' sequences up to nucleotide -120 of the human and murine IL-16 genes …”  
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MEDLINE: 96324400 
Without considering the keyword “genes”, the bold term “IL-16” was wrongly 
classified into the protein type. 
 
2.5 Missing annotations 
This is hard to avoid when the corpus size is huge. GENIA corpus also suffered from 
this problem. The following sentence displays missing annotations: 
“Three additional smaller regions show homology to the ELK-1 and SAP-1 genes…”  
MEDLINE: 94217726 
According to the GENIA ontology, the bold term “ELK-1” should be referred to as 
DNA, but it is missing.  
In order to obtain more consistent annotations and a reliable source for both entity 
linking and relation extraction tasks, we had domain experts carefully check and revise 
the JNLPNA corpus. 
3. Annotation Guideline 
3.1 Annotators 
For revising JNLPBA, we recruited two curators. Both had a biological background, 
curation and natural language processing experiences. Annotator 1 is a Ph.D. candidate 
with biological, chemical and medical background. Annotator 2 is a full-time master 
research assistant with biological, chemical and computer science background. 
Annotator 2 also had extensive curation experiences. Each article was annotated 
independently by the two annotators. Differences were resolved through discussion. 
3.2 Annotation tool 
The curators used the brat annotation tool to manually revise the annotations of the 
JNLPBA corpus according to the annotation guideline.  
3.3 General Rules 
Rule 1: Removing General NEs - In JNLPBA, sometimes nonspecific molecules, 
like “upstream regulatory region”, “60-kDa protein” and “cytokines”, are annotated 
as NEs. However, these terms are too general to be linked to any database ID, like 
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Entrez ID or UniProt ID. Such general terms usually are not labeled as target NEs in 
the BRE tasks, and thus, are removed. 
Rule 2: Adding Missing NEs - Due to the considerable size of JNLPBA, sometimes 
annotations are missed, which are recovered now. 
Rule 3: Adjusting NE Types - Sometimes cell type such as “senescent T cells” is 
mistaken as a cell line. Thus, all NE types are reconfirmed.  
3.4 Specific Rules 
There is an important principle that must be elucidated first before explaining the 
detailed criteria of specific rules. The principle is that, when the target NE and 
surrounding contexts cannot provide any evidence to support the assignment of NE 
type, this NE is labeled as protein. For instance, the paper titled “An essential role for 
NF-kappaB in human CD34 ( + ) bone marrow cell survival.” is insufficient to 
discriminate the NE type of “NF-kappaB”. As a consequence, “NF-kappaB” is labeled 
as protein type since the molecule which is responsible to carry out the biological 
function is protein. 
Rule 1: Adjective rule - Only the adjectives preceding an NE that help biologists 
identify the NE’s are included in the NE boundary. Otherwise, they are removed. 
Moreover, the preserved adjectives often provide the intrinsic properties of described 
NEs. For example, “human” would be included in “human GM-CSF gene” because it 
is related to the NE’s species and can help biologists to determine the NE’s identifier. 
In contrast, “abnormal” would be excluded from “abnormal blast cells” since the 
adjective displays an extrinsic property of target NE. 
Rule 2: Verb rule Ving Event adjective verb rule - If a protein-Ving or protein-
Ved phrase is followed by a general term for the protein type, such as protein or 
transcription factor, protein-Ving/V-ed [protein general term] should be annotated as 
one single protein mention. If a protein-Ving or protein-Ved phrase is followed by a 
specific protein mention, then the first protein and the second protein mention should 
be annotated separately. For example, “Octamer-binding proteins” will be labeled as 
“Octamer-binding proteinsprotein”, but “fibrinogen-binding integrins” will be labeled as 
“fibrinogenprotein-binding integrinsprotein”. 
Rule 3: Preposition rule - Preposition can be inside an NE only when the 
preposition is included in the NE’s full name. For example, “Nuclear factor of 
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activated T cells (NFAT)” can be labeled as “Nuclear factor of activated T cellsprotein 
(NFATprotein)” 
Rule 4: Parenthesis rule - In general, when an abbreviation inside parenthesis 
follows its full name, it should be labeled separately. For instance, “tumor necrosis 
factor (TNF)” should be labeled as “tumor necrosis factorprotein (TNFprotein)”. However, 
if a specifier number follows the parenthesis, then the whole chunk should be labeled 
as an NE. For example, “interleukin (IL) -2” should be labeled as “interleukin (IL) -
2protein”. 
Rule 5: Conjunction rule - Conjunctions can appear inside an NE only when they 
are part of the NE’s full name. E.g., “signal transducers and activators of transcription 
5 (STAT5 )” is labeled as “signal transducers and activators of transcription 5protein 
( STAT5protein )”. However, if a conjunction is used to connect more than one separate 
NE, like “IL-1, 2, and 15”, it is labeled as “IL-1protein , 2right_partial_protein , and 
15right_partial_protein” 
Rule 6: Semantic rule - If the words preceding or following an NE provide 
additional semantic information that may help to disambiguate the identifier or type of 
the NE, they will be included. E.g., “human gene PAX-5” is labeled as “human gene 
PAX-5DNA”. 
Rule 7: Protein rule - Protein suffixes that describe part of a protein, like “motif” 
and “domain”, rather than a full protein are not included in the protein NE. In addition, 
the potential protein NEs usually obtain some similar suffixes to represent properties 
of protein, e.g. protein, receptor, antigen, antibody, enzyme, (transcription) factor and 
kinase. Thus, the NEs ending with above keywords should be labeled as protein NEs. 
Moreover, the molecular mass (e.g., “55 kd” in “55 kd TNFR”) is a clue to classify the 
target NE into protein type rather than DNA or RNA. 
Rule 8: DNA rule - DNA suffixes that describe the function of DNA sequence, like 
“enhancer” and “promoter”, are included as part of DNA. More specifically, when 
there are unique gene names conjugated with the following cis-element evidences, they 
tend to be labeled as DNA types: (onco)gene, genome, DNA, locus, allele, promoter, 
enhancer, LTR, response element, probe and plasmid, e.g. “AP-1 enhancer element”, 
“bcl-2 oncogene”, “gene UL49” and “FasL promoter”. Moreover, the NEs with clear 
chromosome information are also included in annotation, e.g., human chromosome 
11p15, 1p36 and 14q11. In some cases, there is not enough evidence to recognize NE 
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type by its own so the surrounding contexts are taken into account for this situation, 
e.g. “Pax-5 encodes the transcription factor BSAP which plays an essential role …” 
In the above sentence, “Pax-5” is only a gene symbol name without any clue to judge 
its NE type. But the verb “encodes” provides the evidence to classify “Pax-5” since 
DNA is the only one among the five NE types to encode the permanent sequence of a 
functional protein. Lastly, there is a special expression profile in biological literature 
to describe the cloned DNA plasmid. In general, the target NE is tight-conjugated with 
a lowercase “p” in the head of NE, e.g. “pCD41”, “pIL-5 cDNA”. 
Rule 9: Cell rule - The target NEs which match the following features are referred 
to as cell_line: 1. NEs described with obvious cell line symbol, e.g. “Hela”, “Hep2” 
and “A549”; 2. general cell name, cellular morphological or cellular functional 
description ending with “cell line” or “clone”, e.g., “T cell line”, “granulocytic clones” 
and “monocytic cell line”. 
The NEs below are annotated as cell_type: the names are mentioned with specific cell 
type, cellular morphology or cellular functional ending with “cell”, “progenitor” or 
“precursors”, e.g., “thymocytes”, “hematopoietic cells” and “myeloid precursors”. 
Rule 10: Complex rule - If a complex is expressed as “<Protein>/<Protein>”, it 
will be treated as one protein. E.g., “TCR/CD3” is labeled “TCR/CD3protein”. 
Rule 11: Amino or DNA sequence rule - Amino acids and DNA sequences are not 
labeled as NEs. For example, “WGATAR consensus motifs” and “GGAAAGTCCC” 
are not included in the corresponding NE lists. 
Rule 12: Group/family protein - A protein family is a group of proteins which have 
similar functions, and a protein complex is a high-level structure consisting of more 
than one protein. Although, protein families and complexes do not appear in Entrez or 
UniProt databases, these entities are still very important for relation extraction. So, we 
include them in Revised JNLPBA. 
3.5 Inter-annotator Agreement (IAA) Analysis 
To evaluate the consistency of the annotation, we used Cohen's kappa coefficient. As 
shown below, κ is the kappa value. 𝑃0  is the relative observed agreement among 
annotators, and 𝑃𝑒 is the hypothetical probability of chance agreement. 
𝜅 =  
𝑃0 − 𝑃𝑒
1 − 𝑃𝑒
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There are two curators participating in the two-stage annotations. After the first stage, 
the two curators would discuss annotation disagreements and then start the second stage 
annotation. The kappa values are 79.5% and 91.4% in the first and the second stage, 
respectively, which suggests a high level of agreement. 
4. Experiment Results 
We design two experiments to evaluate the effects of using Revised JNLPBA corpus. 
In the first experiment, we compare the performances of commonly-used NER systems 
trained on JNLPBA and Revised JNLPBA respectively. In the second experiment, we 
train the NER systems on the two editions of JNLPBA and evaluate their performances 
on Protein-Protein Interaction Extraction (PPIE) and Biomedical Event Extraction 
(BEE) corpora. PPIE datasets include LLL [12], AImed [13], BioInfer [14], IEPA [15] 
and HPRD50 [16]. BEE datasets include BioNLP 2013 ST GRO, GE, GRN, CG and 
PC datasets [17]. We removed all non-gene and cell-related NE annotations from these 
datasets and combined them into the BRE corpus. 
4.1 Evaluation Metrics 
The performance is given in terms of F1-measure and is calculated by using the 
evaluation script from JNLPBA.  
4.2 BNER Systems 
Three BNER systems were used for comparison, including BANNER [9], Gimli [10], 
and NERsuite [11]. We selected these systems because they are available BNER 
systems and achieved state-of-the-art performances on either JNLPBA or GENETAG. 
All of them are based on Conditional Random Fields (CRF). The following table 
summarized the characteristics of these systems. 
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Table 2. The configurations of the NER systems. 
 BANNER [9] Gimli [10] NERsuite [11] 
Model/Toolkit CRF/MALLET CRF /MALLET CRF/CRFsuite 
Label set BIO BIO IOBES 
Tokenization Simple rule GDep GENIATagger 
Features 
Word Y Y Y 
Chunk Dragon toolkit GDep GENIATagger 
Lexicon Y Y - 
Morphological Y Y Y 
Orthographic Y Y Y 
POS Dragon toolkit GDep GENIATagger 
Stem Dragon toolkit GDep GENIATagger 
Others 
Abbreviation Y Y - 
Ensemble - Y - 
Parentheses Y Y - 
 
4.3 Experiment 1 
In this experiment, JNLPBA training and test set were used for compared systems. 
Table 3 shows the performances of different approaches on the test set. We suspect 
that lower score of BANNER might be that the feature selection in the BANNER 
system was based on the BioCreative II GM dataset rather than the JNLPBA dataset.  
The inconsistencies in the JNLPBA, likely due to annotators with different 
annotation criteria, create a bottleneck on the BNER performances. To alleviate any 
negative effects bringing by this problem, we revised the dataset basis on the annotation 
guideline. The corresponding performances are shown in Table 3. Generally, the overall 
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performances of NER systems can reach at least 10% higher in Revised JNLPBA than 
the original one. 
Table 3. The performances of the NER systems on JNLPBA and Revised JNLPBA. 
System 
JNLPBA Revised JNLPBA 
Precision Recall F-score Precision Recall F-score 
BANNER 66.65 69.34 67.97 89.11 73.51 80.56 
Gimli 72.85 71.62 72.23 91.33 82.84 86.88 
NERSuite 69.95 72.41 71.16 89.13 83.41 86.17 
 
4.4 Experiment 2 
In this experiment, the two JNLPBA corpora were used for training NER open-source 
systems. Subsequently, PPIE and BEE corpora are served as test set to evaluate the 
performances. The F-scores of the systems were shown in Table 4 and 5. The lower 
performance of BNER systems stems from the fact that there is no general consensus 
regarding PPIE and BEE annotations. The definitions of BNE boundaries differ among 
PPIE, BEE, and the Revised JNLPBA/JNLPBA corpora. For example, in JNLPBA and 
Revised JNLPBA, “human Myt1 kinase” is designated as a BNE. However, in the 
BioInfer corpus, only “Myt1” is included in the BNE.  
According to the performance of PPIE based on different training corpora, LLL and 
IEPA get similar but lower effects no matter which training corpus adapted. The results 
are explainable because the abstracts in LLL corpus are mainly collected from bacterial 
domains while the chemical is the major issue of IEPA. In contrast, the performance of 
AImed, Bioinfer, and HPRD50 are relatively higher with both training resources and 
the NER systems trained in Revised JNLPBA corpus perform averagely better than 
their corresponding counterparts which trained in original one. 
In the BEE results, NER systems only reach around 30% performance with two 
training corpora editions in GRO and GRN. By inspecting the data composition of the 
two corpora, GRO included general protein terms and functional protein fragments as 
entities while GRN is derived from BioNLP-ST 2011 BI and LLL corpora which 
present bacteria relevant article as the dominant contents. The distinct biological 
domain and the inclusion of general entities frustrated the system performances which 
15 
are trained on the Revised JNLPBA. On the other hand, the better performances can 
elucidate the entity annotation styles are adaptable for NER systems trained on the 
Revised JNLPBA when GE, CG and PC corpora serve as the test set in comparison. In 
average, NER systems trained on the revised edition can reach 5% higher compared 
with the original ones. 
Table 4. The performances (in %) of the NER systems on the PPIE corpora. 
NER Systems Trained on JNLPBA 
 LLL AImed BioInfer IEPA HPRD50 
 NS GIM BNR NS GIM BNR NS GIM BNR NS GIM BNR NS GIM BNR 
P .369 .500 .354 .526 .547 .511 .649 .678 .634 .365 .468 .366 .517 .534 .503 
R .263 .22 .297 .648 .61 .643 .487 .472 .513 .283 .314 .289 .638 .593 .585 
F .307 .306 .323 .581 .577 .569 .556 .556 .567 .319 .375 .323 .571 .562 .541 
NER Systems Trained on Revised JNLPBA 
 LLL AImed BioInfer IEPA HPRD50 
 NS GIM BNR NS GIM BNR NS GIM BNR NS GIM BNR NS GIM BNR 
P .372 .585 .634 .68 .697 .687 .779 .816 .801 .433 .514 .459 .609 .602 .634 
R .148 .161 .271 .658 .631 .657 .522 .510  .551 .323 .355 .332 .623 .621 .583 
F .212 .253 .380 .669 .663 .672 .625 .628 .653 .370 .420 .385 .616 .611 .607 
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Table 5. The performances (in %) of the NER systems on the BEE corpora. 
NER Systems Trained on JNLPBA 
 GRO GE GRN CG PC 
 NS GIM BNR NS GIM BNR NS GIM BNR NS GIM BNR NS GIM BNR 
P .2 .1993 .194 .4011 .4107 .4091 .4589 .4341 .4155 .6489 .6444 .6241 .5447 .5447 .5445 
R .3948 .3742 .402 .5896 .5286 .6101 .2926 .2445 .2576 .4984 .4539 .4955 .5874 .5415 .6111 
F .2655 .2601 .2617 .4774 .4622 .4898 .3573 .3128 .3181 .5638 .5327 .5524 .5652 .5431 .5759 
NER Systems Trained on Revised JNLPBA 
 GRO GE GRN CG PC 
 NS GIM BNR NS GIM BNR NS GIM BNR NS GIM BNR NS GIM BNR 
P .2394 .2395 .2361 .484 .5046 .5159 .4231 .4684 .4878 .7329 .7654 .7352 .6637 .6324 .6819 
R .3751 .3617 .3268 .5908 .5673 .5689 .1441 .1616 .1747 .5048 .5138 .4365 .6122 .6065 .5868 
F .2923 .2882 .2741 .5321 .5341 .5411 .215 .2403 .2572 .5978 .6148 .5478 .637 .6191 .6308 
 
5. Conclusion 
The progression of biomedical text mining is urgently required in the era of information 
explosion. Each mature machine learning model is built on not only the well-designed 
algorithms but also the reliable validation mechanism. Inconsistent annotations make 
the learning systems confusion. And It is hard to discriminate the truth hidden in the 
biological texts since there are various nomenclature forms depending on the distinct 
domains. With a confidential corpus, researchers can concentrate on improving their 
own systems rather than clarifying the causes of unexpected performance. In this work, 
we propose a revised edition of JNLPBA corpus. Several imperfections found in 
original JNLPBA corpus are pointed out and corrected as much as possible. According 
to the evaluation of different NER systems, we believe that the corpus performs higher 
consistency than before after revision process. The further application adaptability of 
revised JNLPBA is also examined via the open tests on PPIE and BEE corpora. In 
overall, the revised JNLPBA is competent for the systems which required gene mention 
entities training for relation extraction purpose. We envision the revised JNLPBA 
corpus can become another option for the researchers who engage in the BNER or BRE 
issues. 
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